HALO Stock Cash Flow Statements

Halozyme Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Halozyme Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30

operating activities
net income	165,160,000	118,095,000	137,012,000	137,011,000	93,245,000	76,823,000	85,388,000	81,837,000	74,754,000	39,615,000	57,702,000	61,634,000	22,685,000	60,108,000	66,770,000	216,587,000	91,458,000	27,895,000	73,164,000	36,207,000	25,817,000	-6,103,000	-34,397,000	-25,015,000	-14,624,000	1,796,000	-2,126,000	-27,850,000	-22,893,000	-27,461,000	123,882,000	2,749,000	-30,763,000	-32,897,000	-27,386,000	-28,946,000	-26,875,000	-19,816,000	4,318,000	-24,460,000	3,019,000	-15,108,000	-5,274,000	-20,280,000	-16,273,000	-26,548,000	-21,986,303	-19,292,368	-22,911,511	-19,288,369	-20,005,846	-14,021,119	-15,119,181	-18,415,614	5,165,193	3,116,287	-9,635,717	-16,893,674	-12,409,576	-12,150,923	-11,787,477	-12,664,852	-13,910,282	-17,060,025	-14,725,364	-16,825,654	-10,872,158	-11,002,390	-9,953,997	-8,708,391	-7,028,781
adjustments to reconcile net income to net cash from operating activities:
share-based compensation	12,161,000	10,673,000	11,462,000	12,578,000	9,471,000	9,874,000	9,664,000	9,368,000	9,622,000	7,966,000	7,223,000	6,797,000	5,635,000	4,742,000	5,126,000	5,399,000	5,372,000	4,923,000	4,196,000	4,220,000	4,257,000	4,531,000	7,229,000	8,239,000	9,833,000	9,475,000	9,012,000	8,867,000	9,478,000	8,339,000	7,402,000	7,762,000	8,191,000	7,315,000	6,742,000	6,655,000	6,371,000	5,817,000	5,250,000	5,553,000	5,905,000	4,130,000	4,209,000	4,176,000	3,594,000	3,295,000	2,398,058	2,303,662	2,439,649	2,396,687	1,922,392	2,285,052	2,154,928	1,653,570	1,757,359	1,227,900	931,070	1,120,349	1,325,690	1,191,500	1,228,786	1,607,955	1,047,309	1,048,810	821,956	805,198	960,851	1,066,277	863,516	790,948	732,792
depreciation and amortization	2,740,000	2,687,000	2,653,000	2,598,000	2,569,000	2,443,000	2,931,000	2,737,000	2,793,000	2,622,000	2,562,000	2,010,000	1,143,000	778,000	773,000	751,000	735,000	738,000	800,000	803,000	824,000	857,000	1,042,000	1,002,000	1,034,000	990,000	590,000	612,000	620,000	566,000	493,000	496,000	570,000	602,000	644,000	654,000	623,000	489,000	459,000	402,000	395,000	421,000	458,000	464,000	443,000	397,000	333,450	301,777	297,036	294,664	286,168	272,202	237,793	244,210	238,682	286,750	326,181	343,763	364,533	389,372	410,257	395,176	368,491	351,432	328,639	290,789	280,504	248,379	228,206	213,529	153,196
amortization of intangible assets	17,762,000	17,762,000	17,762,000	17,762,000	17,762,000	17,763,000	17,762,000	20,341,000	17,835,000	17,835,000	4,552,000	27,193,000
amortization of debt discount	1,852,000	1,846,000	1,844,000	1,841,000	1,835,000	1,830,000	1,828,000	1,824,000	1,817,000	1,835,000	1,832,000	3,925,000	1,111,000	971,000	968,000	968,000	965,000	741,000	3,596,000	3,552,000	3,510,000	3,478,000	1,721,000	209,000	248,000	306,000
accretion of premium on marketable securities	-1,134,000	-1,709,000
realized gain on marketable securities			0	0	0	-7,000
loss on disposal of equipment			-149,000	0			94,000	0				0	0	80,000																	2,000	0	0	44,000																								5,111	-1,178	4,508	5,101	0	0	0	2,685	-5,225	925	0	9,029		0
lease payments recognized	257,000	253,000	204,000	354,000					301,000	320,000
deferred income taxes	-7,094,000	-2,858,000	-15,292,000	292,000	14,241,000	1,291,000	9,423,000	9,702,000	11,507,000	3,874,000	14,676,000	25,701,000	-13,298,000	12,926,000	-12,953,000
changes in operating assets and liabilities
accounts receivable, net and other contract assets	-11,718,000	3,834,000	-22,712,000	-71,220,000	-18,621,000	38,308,000	-16,885,000	28,853,000	-51,496,000	36,189,000		-43,934,000	-9,465,000	-22,787,000		41,097,000	-64,805,000	9,339,000										5,926,000
inventories	-14,540,000	-586,000	-7,726,000	1,980,000	-21,402,000	-40,233,000	1,469,000	3,634,000	-24,737,000	-7,250,000	-2,945,000	-5,511,000	-15,323,000	6,298,000	2,219,000	2,725,000	-86,000	2,513,000	-3,050,000	-9,426,000	-6,819,000	-12,093,000	6,692,000	7,849,000	-12,659,000	-8,616,000	-4,341,000	-9,881,000	-4,010,000	752,000	4,185,000	5,841,000	-882,000	333,000	-1,771,000	-2,097,000	-410,000	-856,000	1,612,000	-3,378,000	-241,000	-1,076,000	510,000	198,000	-349,000	-595,000	-2,323,692	-1,379,291	270,388	-66,691	-402,169	-287,111	-929,520
prepaid expenses and other assets	-36,068,000	-4,995,000	5,621,000	38,483,000	-43,543,000	4,795,000	-1,201,000	-8,450,000	4,868,000	8,881,000	5,295,000	-5,040,000	-151,000	-9,168,000	-5,042,000	-682,000	-3,496,000	-2,335,000	4,085,000	-2,010,000	-3,390,000	3,833,000	-4,696,000	-770,000	-12,722,000	-818,000	1,782,000	1,676,000	-3,214,000	-5,939,000	-6,963,000	1,309,000	3,021,000	4,668,000	4,541,000	965,000	2,642,000	-2,522,000	-14,774,000	436,000	-593,000	-843,000	-363,000	-674,000	1,024,000	-252,000	-59,278	1,964,119	-1,157,225	1,210,965	-1,134,874	-1,308,409	-577,817	-4,034,428	-596,562	-318,259	337,903	1,170,660	-215,327	-355,522	-2,746,930	1,368,238	-230,430	360,751	-481,187	1,123,869	-1,819,198	357,041	-238,181	-177,350	-504,052
accounts payable and accrued expenses	-29,693,000	9,219,000	50,186,000	-23,182,000	1,304,000	18,685,000	-9,479,000	-1,951,000	22,890,000	-24,006,000	326,000	-5,114,000	35,333,000	-6,010,000	3,473,000	-2,513,000	6,833,000	-6,626,000	-1,074,000	-2,610,000	-9,903,000	-27,621,000	11,447,000	-8,496,000	9,568,000	-7,881,000	9,851,000	2,892,000	5,514,000	-12,561,000	11,416,000	3,610,000	5,016,000	-4,413,000	1,157,000	3,410,000	-246,000	-4,565,000	7,855,000	4,320,000	2,900,000	-1,209,000	-2,509,000	-1,481,000	-245,000	3,419,000	-8,182,186	3,540,633	10,549,196	1,980,892	1,494,709	7,708	-3,609,171	2,895,641	-1,100,514	1,688,431	-2,771,781	5,621,096	522,732	-2,068,744	-637,995	-1,817,319	433,115	522,042	-1,138,071	2,702,412	1,719,623	-416,451	782,762	851,575	1,703,432
net cash from operating activities	99,711,000	154,221,000	178,467,000	115,376,000	55,794,000	129,427,000	102,354,000	132,411,000	66,842,000	86,964,000	82,453,000	69,635,000	40,225,000	47,797,000	82,516,000	121,739,000	36,889,000	58,296,000		6,084,000	3,294,000	-4,844,000	-26,625,000	-29,588,000	-24,786,000	-4,424,000	10,462,000	-18,927,000	-18,858,000	-22,177,000	153,249,000	20,259,000	-16,996,000	-22,459,000	-15,767,000	-8,748,000	-12,845,000	-13,023,000	-15,197,000	-16,985,000	8,938,000	-13,839,000	-939,000	-13,183,000	-15,766,000	-17,630,000	-15,219,954	-12,413,897	-10,954,726	-10,750,902	-14,298,123	-13,755,168	-19,357,615	-13,553,841	-13,443,456	3,738,938	-11,092,066	-7,375,069	-11,616,065	-13,791,719	-12,602,653	-10,967,720	-14,482,926	-10,918,229	-3,779,390	-9,039,412	-10,624,822	-10,200,362	-5,509,268	-7,625,669	4,953,385
capex	-1,770,000	-462,000	-3,092,000	-1,695,000	-3,599,000	-2,030,000	-2,596,000	-2,944,000	1,888,000	-10,987,000	-2,344,000	-1,008,000	-941,000	-181,000	-158,000	-636,000	-579,000	18,000		199,000	-706,000	233,000	-641,000	-1,398,000	-1,023,000	-727,000	-3,073,000	-333,000	-418,000	-839,000	-860,000	-161,000	-230,000	-99,000	-447,000	-424,000	-1,167,000	-1,099,000	-1,634,000	-336,000	-260,000	-130,000	-236,000	-371,000	-350,000	-411,000	-1,358,079	-325,159	-80,183	-534,097	298,355	-585,416	628,535	-374,043	-60,458	-17,881	-186,228	-426,636	41,463	-142,954	-104,611	-727,134	123,527	-603,221	-110,700	-193,018	-505,271	-267,005	-205,018	-582,471	-887,467
free cash flows	97,941,000	153,759,000	175,375,000	113,681,000	52,195,000	127,397,000	99,758,000	129,467,000	68,730,000	75,977,000	80,109,000	68,627,000	39,284,000	47,616,000	82,358,000	121,103,000	36,310,000	58,314,000		6,283,000	2,588,000	-4,611,000	-27,266,000	-30,986,000	-25,809,000	-5,151,000	7,389,000	-19,260,000	-19,276,000	-23,016,000	152,389,000	20,098,000	-17,226,000	-22,558,000	-16,214,000	-9,172,000	-14,012,000	-14,122,000	-16,831,000	-17,321,000	8,678,000	-13,969,000	-1,175,000	-13,554,000	-16,116,000	-18,041,000	-16,578,033	-12,739,056	-11,034,909	-11,284,999	-13,999,768	-14,340,584	-18,729,080	-13,927,884	-13,503,914	3,721,057	-11,278,294	-7,801,705	-11,574,602	-13,934,673	-12,707,264	-11,694,854	-14,359,399	-11,521,450	-3,890,090	-9,232,430	-11,130,093	-10,467,367	-5,714,286	-8,208,140	4,065,918
investing activities
purchases of marketable securities	-102,760,000	-139,639,000	-51,444,000	-303,974,000	-93,420,000	-198,763,000	-21,294,000	-161,698,000	0	-109,919,000	-29,519,000	0	-40,874,000	-184,815,000	-369,161,000	-41,428,000	-120,946,000	-120,980,000	-64,697,000	-83,251,000	-14,980,000	-63,257,000	-148,177,000	-7,898,000	-66,014,000	-167,670,000	-38,469,000	-62,728,000	-95,254,000	-114,661,000	-199,439,000	-36,856,000	-107,062,000	-54,830,000	-3,008,000	-14,005,000	-11,968,000	-126,431,000	-25,122,000	-13,176,000	1,000	-33,185,000	233,000	-1,000	-24,111,000	-65,005,000	0	0	-1	-48,946,615
proceeds from sales and maturities of marketable securities	189,111,000	50,167,000	83,976,000	138,008,000	53,963,000	119,627,000	15,599,000	81,192,000	53,371,000	61,134,000		0
purchases of property and equipment	-1,563,000	-950,000	-3,052,000	-1,517,000	-2,582,000	-3,545,000	-2,596,000	-2,944,000	1,623,000	-11,377,000	-2,344,000	-1,008,000	-968,000	-490,000	-158,000	-496,000	-533,000	-270,000	-1,699,000	-176,000	-515,000	-114,000	-641,000	-1,104,000	-1,368,000	-927,000	-3,073,000	-333,000	-418,000	-839,000	-860,000	-161,000	-230,000	-99,000	-447,000	-424,000	-1,167,000	-1,099,000	-1,634,000	-336,000	-260,000	-130,000	-236,000	-371,000	-350,000	-411,000	-1,358,079	-325,159	-80,183	-534,097	-167,516			-556,987	-38,959	-29,539	-203,023	-330,737	-60,639	-106,128	-149,040	-563,367	-150,945	-427,758	-318,951	-252,370	-435,351	-267,005	-205,018	-582,471	-887,467
net cash from investing activities	84,788,000	-90,422,000	29,480,000	-167,483,000	-42,039,000	-82,681,000	-8,291,000	-83,450,000	54,994,000	-60,162,000	-1,746,000	-1,008,000	-434,946,000	-49,305,000	-299,469,000	-16,954,000	-44,616,000	-45,250,000	58,441,000	-30,095,000	11,899,000	38,109,000	-122,818,000	40,999,000	47,457,000	28,813,000	10,809,000	35,191,000	-7,607,000	-35,900,000	-148,988,000	30,283,000	-49,292,000	4,265,000	21,045,000	8,246,000	-435,000	-105,622,000	-14,756,000	20,293,000	10,771,000	-10,420,000	13,482,000	2,628,000	-5,870,000	-43,191,000	2,016,921	-325,159	-80,184	-49,480,712	-167,516	-721,493	15,844	-556,987	-38,959	-29,539	-203,023	-330,737	-60,639	-106,128	-149,040	-563,367	-150,945	-427,758	-318,951	-252,370	-435,351	-267,005	-205,018	-582,471	-887,467
financing activities
repurchase of common stock							-252,300,000	0	0	-150,083,000	-1,000				-160,321,000	-64,716,000	-48,842,000	-76,179,000	-40,147,000	-56,400,000	-1,996,000	-51,574,000
proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement			3,585,000	18,561,000			2,380,000	4,101,000	2,446,000	-1,048,000	6,969,000	2,636,000	3,821,000	624,000	4,310,000	4,648,000	4,180,000	-602,000	12,748,000	12,546,000	18,382,000	19,717,000	8,131,000	2,075,000	4,467,000	-449,000	2,063,000	3,538,000	3,141,000	4,977,000	5,090,000	3,703,000	4,376,000	-393,000
net cash from financing activities	-298,966,000	-3,321,000	-246,415,000	18,561,000	9,482,000	-489,000	-249,920,000	4,101,000	2,446,000	-164,614,000	6,329,000	-12,400,000	367,818,000	624,000	-156,011,000	-60,068,000	-44,757,000	338,701,000	-27,399,000	-43,854,000	13,593,000	-48,624,000	210,420,000	-19,250,000	-16,225,000	-21,730,000	-18,354,000	-16,418,000	-16,374,000	-12,651,000	82,000	-890,000	135,845,000	-3,382,000	279,000	476,000	5,420,000	144,446,000	1,731,000	437,000	3,773,000	7,157,000	2,471,000	795,000	1,201,000	110,034,000	23,067,849	2,303,636	-55,343	-251,846	38,913	-90,026	83,124,548	606,997	695,068	1,578,007	1,868,540	1,121,066	60,204,866	33,957	463,503	1,359,801	3,028,900	38,521,687	2,447,498	514,643	1,143,079	319,098	593,609	772,474	453,690
net increase in cash and cash equivalents																																			5,557,000	-26,000	-7,860,000	25,801,000	-28,222,000	3,745,000	23,482,000	-17,102,000	15,014,000	-9,760,000	-20,435,000	49,213,000	9,864,816	-10,435,420	-11,090,253	-60,483,460	-14,426,726	-14,566,687	63,782,777	-13,503,831				-6,584,740	48,528,162			-10,171,286	-11,604,971			-8,777,139	-9,917,094	-10,148,269	-5,120,677	-7,435,666	4,519,608
cash and cash equivalents at beginning of period																																			0	0	0	43,292,000	0	0	0	61,389,000	0	0	0	27,357,000	0	0	0	99,501,264	0	0	52,825,527	0	0	0	83,255,848	0	0	0	67,464,506	0	0	0	63,715,906	0	0	0	97,679,085		0
cash and cash equivalents at end of period																																			5,557,000	-26,000	-7,860,000	69,093,000	-28,222,000	3,745,000	23,482,000	44,287,000	15,014,000	-9,760,000	-20,435,000	76,570,000	9,864,816	-10,435,420	-11,090,253	39,017,804	-14,426,726	-14,566,687	116,608,304	-13,503,831	-12,787,347	5,287,406	73,829,299	-6,584,740	48,528,162	-13,863,890	55,176,316	-10,171,286	-11,604,971	27,175,700	62,065,063	-8,777,139	-9,917,094	-10,148,269	92,558,408		4,519,608
supplemental disclosure of non-cash investing and financing activities
amounts accrued for purchases of property and equipment	-207,000	488,000	-40,000	-178,000	-1,017,000	1,515,000			265,000	390,000			27,000	309,000		-140,000	-46,000	288,000		375,000	-191,000	347,000		-294,000	345,000	200,000
right-of-use assets obtained in exchange for lease obligation	637,000	95,000	456,000	1,156,000	224,000	1,242,000			631,000	406,000						0	139,000	179,000		52,000	20,000	1,589,000		732,000	0	165,000
taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plan		-3,321,000
net increase in cash, cash equivalents and restricted cash		60,478,000	-38,468,000	-33,546,000	23,237,000	46,257,000	-155,857,000				87,036,000	56,227,000	-26,903,000	-884,000	-372,964,000	44,717,000	-52,484,000	351,747,000	81,962,000	-67,865,000	28,786,000	-15,359,000	60,977,000	-7,839,000	6,446,000	2,659,000	2,917,000	-154,000			4,343,000	49,652,000	69,557,000	-21,576,000
cash, cash equivalents and restricted cash at beginning of period		115,850,000	0	0	0	118,370,000	0	0	0	234,695,000	0	0	0	119,219,000	0	0	0	148,203,000	0	0	0	120,679,000	0	0	0	58,436,000	0	0	0	169,240,000	0	0	0	67,264,000
cash, cash equivalents and restricted cash at end of period		176,328,000	-38,468,000	-33,546,000	23,237,000	164,627,000	-155,857,000	53,062,000	124,282,000	96,883,000	87,036,000	56,227,000	-26,903,000	118,335,000	-372,964,000	44,717,000	-52,484,000	499,950,000	81,962,000	-67,865,000	28,786,000	105,320,000	60,977,000	-7,839,000	6,446,000	61,095,000	2,917,000	-154,000	-42,839,000	98,512,000	4,343,000	49,652,000	69,557,000	45,688,000
accretion of (premium) discount on marketable securities
contingent liability fair value measurement adjustment							0
recognition of deferred revenue								-175,000			-921,000	-451,000	-623,000	-499,000	-499,000	-498,000			-249,000	0	-3,264,000	-606,000	501,000	-3,499,000	-499,000	-499,000	-499,000	-499,000	0	-1,834,000	-2,320,000	-1,869,000	-600,000	-1,723,000
induced conversion expense related to convertible notes											0				0	0	0	20,960,000
other											1,000				1,000				0	-3,000	-6,000	-4,000	-6,000	-9,000	-3,000	11,000	1,000	3,000	-11,000	-2,000	-10,000	-13,000	12,000	-5,000
acquisitions of business, net of cash acquired											0	0
proceeds from sale of assets
proceeds from term loan											0	0
repayment of term loan											0
proceeds from revolving credit facilities											0	0
repayment of revolving credit facilities											0
repayment of 2024 convertible notes							0	0	0	-13,483,000
proceeds from issuance of 2028 convertible notes											0
purchase of capped call											0
payment of debt issuance cost											-639,000	-462,000			0	0	-95,000	-329,000				-68,000
supplemental disclosure of cash flow information
interest paid
income taxes paid
common stock issued for conversion of 2024 convertible notes									0	125,000
adjustments to reconcile net income to net cash from operating activities
accretion of discount on marketable securities				-3,121,000
amortization of premium on marketable securities						-2,365,000
lease payments deferred						220,000					-265,000	-244,000	-211,000	-183,000	-183,000	-183,000	-182,000	-203,000		-270,000	-268,000	-221,000
taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans						-489,000
amortization of (premium) discounts on marketable securities							-2,489,000	-1,488,000	-1,425,000	-917,000
realized loss on marketable securities											0	0
proceeds from issuance of 2027 convertible notes
income taxes paid (received)
adjustments to reconcile net income to net cash from in operating activities:
changes in operating assets and liabilities:
acquisition of business, net of cash acquired
proceeds from the sale of assets												0
payment of debt issuance costs
net decrease in cash, cash equivalents and restricted cash									124,282,000	-137,812,000																				-70,728,000
supplemental disclosure of non-cash investing and financing activities:
operating activities:
amortization of (accretion of discounts) premiums on marketable securities
gain on disposal of equipment																				-34,000	0	-597,000																													378
deferral of unearned revenue																											0	0			22,337,000
loss on impairment of right-of-use asset																			52,000
accounts receivable																			-35,179,000	-25,150,000	-7,652,000	29,693,000	-18,698,000			1,841,000				15,044,000	-7,438,000	-222,000	-2,021,000	3,228,000	1,998,000	5,549,000	2,316,000	6,867,000	-24,018,000	1,346,000	-2,013,000	1,424,000	-874,000	4,620,000	-1,939,000	-1,859,000	15,424,658	-13,689,914	-456,095	5,327,354	1,222,823	-136,266	-3,288,365	3,975,439	-1,742,112	-2,764,467	596,943	293,808	-368,305	-233,025	2,223,163	-2,654,159	-696,657	-416,256	6,787,573	-5,768,555	-334,865	-30,606	-350,559	-369,440	-14,956
investing activities:
proceeds from maturities of marketable securities														136,000,000	69,850,000	24,970,000	76,863,000	76,000,000	124,622,000	53,209,000	27,394,000	100,742,000	26,000,000	50,001,000	114,839,000	197,410,000	52,351,000	98,252,000	88,065,000	79,600,000	51,311,000	67,300,000	58,000,000	59,194,000	24,500,000	22,675,000	12,700,000	21,908,000	12,000,000	33,805,000	11,030,000	22,895,000	13,485,000	3,000,000	18,591,000	22,225,000
financing activities:
repayment of long-term debt															0	0	0	-369,064,000	0	0	-2,861,000	-16,699,000	-44,784,000	-21,325,000	-20,692,000	-21,281,000	-20,417,000	-19,956,000	-19,515,000	-17,628,000	-5,007,000	-4,595,000	-3,404,000	-2,989,000	35,000	-35,000	-50,365,000	-3,885,000
accretion of discounts on marketable securities												185,000	259,000	541,000		573,000	594,000	351,000		280,000	188,000	9,000		-472,000	-797,000	-936,000
common stock issued for induced conversion related to convertible notes																0	0	7,865,000
adjustments to reconcile net income to net cash from (used) in operating activities:
proceeds from issuance of long-term debt															0	0	0	784,875,000																	1,000	0	54,959,000	148,046,000
debt issuances cost included in accounts payable																		95,000
amortization of premiums (accretion of discounts) on marketable securities
(gain) loss on disposal of equipment																																																						-574	-336	0	-656
loss on extinguishment of debt
proceeds from disposal of property and equipment																			215,000	123,000	0	738,000
pending settlement of common stock repurchase
deferral of lease payments																									-110,000	-93,000
net cash provided (used in) by operating activities
(accretion of discounts) amortization of premiums on marketable securities																													-705,000	-565,000	-209,000
lease payments (deferred) recognized																							-155,000
recognition of deferred rent																															-60,000	-56,000	45,000	-114,000
proceeds from issuance of common stock																															-1,000	2,000											0	0	0	107,713,000					0	0	81,476,845					0				0	0							0	0
leasehold improvements paid by lessor
non-cash interest expense																											-455,000	303,000	345,000	1,352,000	519,000	386,000	369,000	487,000	452,000	601,000	789,000	1,054,000	358,000	357,000	356,000	172,000	415,000	432,000	432,000	746,000	-880,693	283,686	282,732	470,084
payment-in-kind interest expense on long-term debt																																			4,032,000	3,674,000	3,588,000	1,890,000
deferral of rent expense
deferral (recognition) of rent expense																												-80,000	26,000	132,000
amortization of premiums on marketable securities																																	46,000	16,000	47,000	108,000	184,000	213,000	180,000	151,000	223,000	325,000	395,000	375,000
proceeds from issuance of common stock under equity incentive plans																																			243,000	511,000	826,000	285,000	1,731,000	437,000	3,773,000	7,157,000	2,471,000	-137,000	1,280,000	3,174,000	3,082,599	1,929,851	9,319	57,277
supplemental disclosure of cash flow information:
deferred revenue																																				772,000	-1,730,000	-1,524,000	3,189,000	-1,643,000	-950,000	-2,007,000	1,908,000	-993,000	-4,154,000	4,729,000	-234,666	13,276,267	-542,962	-3,201,344	2,315,597	-577,782	1,731,577	508,750	-17,249,825	262,783	-731,269	168,708	-757,948	-574,347	-1,225,054	2,792,679	-993,934	4,501,437	4,733,554	8,500,848	-684,023	-622,726	2,984,866	-572,267	9,473,068
other liabilities																																				-93,000	-97,000	-70,000	366,000	-69,000	-63,000	-68,000	-47,000	-20,000	-21,000	73,000
restricted cash																																															0	0	0	-100,000
capitalized property and liability associated with a build-to-suit lease arrangement																																															-2,550,000	450,000
payments for tax withholding for restricted stock units vested																																													-79,000	-853,000			-64,662	-309,123
amortization of discount on investments																																														-1,035,000
amortization of premiums on investments, net of accretion of discounts																																															299,429	318,873	315,407	181,916
deferred rent																																															-8,731	-41,341	-41,341	42,940	2,699	10,557	49,129	82,985	104,253	74,888	-89,688	-88,048	-81,982	-72,213	-72,504	-74,141	-65,818	10,352	16,264	52,801	-307	170,285	140,705	333,334
proceeds from sales of marketable securities
gain on disposals of equipment																																																					-6,988
interest and fees paid																																																566,250	566,250	396,938
property and equipment purchases in accounts payable and accrued expenses																																																-113,960	168,307	35,157
proceeds from disposals of property and equipment																																																					15,844
adjustments to reconcile net income to net cash from operating activies:
accounts payable for purchases of property and equipment																																																			465,871	-585,416	628,535	182,944	-21,499	11,658	16,795	-95,899	102,102	-36,826	44,429	-163,767	274,472	-175,463	208,251	59,352	-69,920
proceeds from exercise of stock options and restricted stock units
proceeds from exercise of stock options																																																					1,647,703			1,578,007	1,868,540	1,121,066	239,807	33,957	463,503	250,872	186,186	347,316	233,983	85,780	92,711	71,616	593,609	136,958	109,484
inventory																																																						-463,820	-19,594	164,625	-55,052	883,158	5,296			78,703	-434,720	-236,772	-125,439	84,105	123,826	29,829	24,385	9,835	-93,043
proceeds from exercise of warrants																																																														1,108,929	2,842,714	0	2,213,515	428,863	1,050,368			635,516	344,206
proceeds from exercises of stock options
net decrease in cash and cash equivalents																																																								5,287,406	-9,426,549				-12,288,190				-1,650,843
issuance of stock options for services
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
cash flows from operating activities:
share-based compensation expense
issuance of common stock and stock options for goods and services
cash flows from investing activities:
purchase of property and equipment
cash flows from financing activities:
proceeds from issuance of common stock — net
cash and cash equivalents, beginning of period
cash and cash equivalents, end of period
proceeds from exercise of stock options — net
proceeds from exercise of warrants — net
contributed capital — net
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
supplemental disclosures of cash flow information:
non cash investing and financing activities:
conversion of contributed capital to common stock
conversion of series c preferred stock to common stock
accrued cost for redemption of unexercised callable warrants
cash paid for income taxes

We provide you with 20 years of cash flow statements for Halozyme Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Halozyme Therapeutics stock. Explore the full financial landscape of Halozyme Therapeutics stock with our expertly curated income statements.

The information provided in this report about Halozyme Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.